NEW YORK (Reuters) - A leading doctor expressed concerns about the heart risks of GlaxoSmithKline Plc’s diabetes drug Avandia in a letter to the U.S. Food and Drug Administration seven years ago.John Buse, president-elect of the American Diabetes Association and faculty member at the University of North Carolina in Chapel Hill, cited “a worrisome trend in cardiovascular deaths and severe adverse events” among patients using the drug in a letter to the agency in March 2000.
